CORCEPT THERAPEUTICS INC (CORT) Stock News

Exploring NASDAQ:CORT's high growth characteristics.

Is CORCEPT THERAPEUTICS INC (NASDAQ:CORT) suited for high growth investing?

Exploring the Growth Potential of NASDAQ:CORT as It Nears a Breakout.

CORCEPT THERAPEUTICS INC (NASDAQ:CORT), a strong growth stock, setting up for a breakout.

NASDAQ:CORT is not too expensive for the growth it is showing.

For those who appreciate growth without the sticker shock, NASDAQ:CORT is worth considering.

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism

Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism

Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes

Corcept Therapeutics reports positive Phase 4 CATALYST results, showing Korlym significantly improves hemoglobin A1c in hypercortisolism patients.

Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes

Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)

NewAmsterdam Pharma Stock Hits 90-Plus RS Rating

NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95.

Notable Thursday Option Activity: BTU, CORT, HIPO

12 Health Care Stocks Moving In Wednesday's After-Market Session

Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Corcept Therapeutics Incorporated (NASDAQ: CORT)

/PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Corcept Therapeutics Incorporated (NASDAQ: CORT) on behalf of the company's...

CORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q2 2024

CORT stock results show that Corcept Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

CORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Corcept Therapeutics (NASDAQ:CORT) just reported results for the second quarter...

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

MENLO PARK, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

MENLO PARK, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter...